Little Green Pharma (LGP) has been granted a Good Manufacturing Practices (GMP) licence by the TGA for its recently commissioned manufacturing facility in Western Australia.
The GMP licence marks the culmination of a two-year regulatory strategy for LGP, which now holds more than 20 state and federal operating authorisations.
These will allow the company to operate a fully in-house and vertically integrated cannabis cultivation, production, manufacturing and wholesaling supply chain to supply LGP-branded medicinal cannabis products to Australian and international markets.
Commenting on the grant, LGP managing director Fleta Solomon said: “The grant represents the culmination of LGP’s long-term regulatory strategy and is a clear watershed moment.
“It differentiates the company as the only fully TGA and Office of Drug Control-licensed and permitted medicinal cannabis company listed on the ASX with local Australian cultivation, manufacturing and wholesaling capacity, as well as brands in market.
“This end-to-end capability allows us to more effectively manage costs, focus on higher-margin aspects of the supply chain and supply LGP-branded GMP-grade medicinal cannabis products into the highly regulated markets of the European Union.”
LGP said operating an in-house manufacturing capability would help it avoid potential future congestion and competition for outsourced Australian manufacturing capacity and allow it to focus on ‘de-bottlenecking’ and identifying further manufacturing cost efficiencies. It will also facilitate expedited inspection and auditing by offshore distributors.
The company plans to develop its capability to manufacture additional GMP-licenced cannabis products and other pharmaceutical formulations and potentially offer toll extraction and manufacturing services to other producers.
The manufacturing facility was constructed with funding support from the West Australian Government.
